Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 980 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 980 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.39, for a total value of $116,022.20. Following the transaction, the chief executive officer now directly owns 137,658 shares of the company’s stock, valued at $16,297,330.62. This trade represents a 0.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kyle Gano also recently made the following trade(s):

• On Friday, January 31st, Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.87, for a total value of $235,572.67.
• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Trading Up 0.3 %

NBIX stock opened at $117.18 on Thursday. The firm has a market cap of $11.86 billion, a PE ratio of 35.62 and a beta of 0.33. The stock has a 50-day moving average price of $138.49 and a 200-day moving average price of $131.02. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers grew its holdings in Neurocrine Biosciences by 7.9% in the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after purchasing an additional 519 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $510,000. CWM LLC increased its position in Neurocrine Biosciences by 15.1% in the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after buying an additional 1,035 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Neurocrine Biosciences by 29.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 7,964 shares of the company’s stock worth $918,000 after buying an additional 1,803 shares during the period. Finally, Redhawk Wealth Advisors Inc. boosted its holdings in Neurocrine Biosciences by 9.1% in the third quarter. Redhawk Wealth Advisors Inc. now owns 9,639 shares of the company’s stock worth $1,111,000 after acquiring an additional 807 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NBIX. Morgan Stanley lifted their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. HC Wainwright decreased their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Bank of America dropped their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Barclays boosted their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $166.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.